Plenary Session:

J. N. Poynter, G. Rennert, J. D. Bonner, H. S. Rennert, J. K. Greenson, and S. B. Gruber

HMG CoA reductase inhibitors and the risk of colorectal cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 1. [Abstract]  

R. Stupp, W. P. Mason, M. J. Van Den Bent, M. Weller, B. Fisher, M. Taphoorn, A. A. Brandes, G. Cairncross, D. Lacombe, and R. O. Mirimanoff

Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group
J Clin Oncol (Meeting Abstracts) 2004 22: 2. [Abstract]  

D. P. Petrylak, C. Tangen, M. Hussain, P. N. Lara, J. Jones, M. E. Talpin, P. Burch, G. Greene, E. Small, and E. D. Crawford

SWOG 99–16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA)
J Clin Oncol (Meeting Abstracts) 2004 22: 3. [Abstract]  

M. A. Eisenberger, R. De Wit, W. Berry, I. Bodrogi, A. Pluzanska, K. Chi, S. Oudard, T. Christine, N. James, and I. Tannock

A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2004 22: 4. [Abstract]  

J. A. Sloan, H. McLeod, D. Sargent, X. Zhao, C. Fuchs, R. Ramanathan, S. Williamson, B. Findlay, R. Morton, and R. M. Goldberg

Preliminary evidence of relationship between genetic markers and oncology patient quality of life (QOL)
J Clin Oncol (Meeting Abstracts) 2004 22: 5. [Abstract]  

Breast Cancer:

M. Yoshimoto, M. Makita, S. Nishimura, K. Tada, F. Kasumi, F. Akiyama, Y. Hoshikawa, Y. Miki, M. Matsuura, and T. Noda

Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 500. [Abstract]  

L. Gianni, M. Zambetti, K. Clark, J. Baker, M. Cronin, G. Mariani, J. Rodriguez, M. L. Carcangiu, P. Valagussa, and S. Shak

Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 501. [Abstract]  

J. Hannemann, H. M. Oosterkamp, C. A. J. Bosch, C. Loo, A. Witteveen, A. Velds, E. J. T. H. Rutgers, S. Rodenhuis, and M. Van de Vijver

Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 502. [Abstract]  

L. Pusztai, J. Wang, K. Coombes, S. Hoersch, M. Ayers, J. Ross, K. Hess, G. Hortobagyi, W. Symmans, and J. Stec

Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips
J Clin Oncol (Meeting Abstracts) 2004 22: 503. [Abstract]  

M. D. Schnall, J. Blume, D. Bluemke, S. Smazal, G. Deangelis, S. Harms, C. Kuhl, N. Hylton, and C. Gatsonis

MRI detection of multi focal breast carcinoma: Report from the International Breast MRI Consortium
J Clin Oncol (Meeting Abstracts) 2004 22: 504. [Abstract]  

S. B. Holmberg, D. Crivellari, D. Zahrieh, J. F. Forbes, P. Rey, D. M. Dent, P. Schaefer, J. Bernhard, I. Campbell, and C.-M. M. Rudenstam

A randomized trial comparing axillary clearance versus no axillary clearance in older patients ( 60 years) with breast cancer: First results of International Breast Cancer Study Group Trial 10–93
J Clin Oncol (Meeting Abstracts) 2004 22: 505. [Abstract]  

R. E. Mansel, A. Goyal, L. Fallowfield, and R. G. Newcombe

Sentinel node biopsy in breast cancer: The first results of the randomized multicenter ALMANAC Trial
J Clin Oncol (Meeting Abstracts) 2004 22: 506. [Abstract]  

B. Lloveras, M. Monzo, R. Colomer, A. Llombart, M. Ramos, J. I. Mayordomo, D. Fuster, and E. Alba

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 507. [Abstract]  

V. Stearns, D. F. Hayes, Y. Jin, L. Ullmer, A. Nguyen, A. M. Storniolo, D. Flockhart, and Z. Desta

The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxife
J Clin Oncol (Meeting Abstracts) 2004 22: 508. [Abstract]  

D. F. Hayes, M. Cristofanilli, G. T. Budd, M. Ellis, A. Stopeck, J. Matera, M. C. Miller, G. V. Doyle, W. J. Allard, and L. W. Terstappen

Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): A prospective, multi-institutional tria
J Clin Oncol (Meeting Abstracts) 2004 22: 509. [Abstract]  

K. S. Albain, S. Nag, G. Calderillo-Ruiz, J. P. Jordaan, A. Llombart, A. Pluzanska, M. Pawlicki, A. S. Melemed, J. O'Shaughnessy, and J. M. Reyes

Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva
J Clin Oncol (Meeting Abstracts) 2004 22: 510. [Abstract]  

G. Comella, D'Aiuto, P. Comella, R. Thomas, I. Capasso, P. Silvestro, A. Russo, A. Petrillo, L. Lapenta, and G. Frasci

Comparison of weekly cisplatin-epirubicin-paclitaxel (PET) with triweekly epirubicin-paclitaxel (ET) in locally advanced breast cancer (LABC). SICOG 9908 phase III tria
J Clin Oncol (Meeting Abstracts) 2004 22: 511. [Abstract]  

A. D. Seidman, D. Berry, C. Cirrincione, L. Harris, L. Dressler, H. Muss, L. Norton, E. Winer, and C. Hudis

CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
J Clin Oncol (Meeting Abstracts) 2004 22: 512. [Abstract]  

V. J. Möbus, M. Untch, A. du Bois, H.-J. Lueck, C. Thomssen, W. Kuhn, C. Kurbacher, U. Nitz, R. Kreienberg, and C. Jackisch

Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients ( 4 +LN). First results of an AGO-trial
J Clin Oncol (Meeting Abstracts) 2004 22: 513. [Abstract]  

R. Paridaens, P. Therasse, L. Dirix, L. Beex, M. Piccart, D. Cameron, T. Cufer, K. Roozendaal, M. Nooij, and M.-R. Mattiacci

First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group
J Clin Oncol (Meeting Abstracts) 2004 22: 515. [Abstract]  

L. Asmar, J. Cantrell, S. J. Vukelja, J. E. Pippen, J. O'Shaughnessy, J. L. Blum, R. J. Brooks, S. Mull, H. Guo, and S. Jones

A planned comparison of menopausal symptoms during the first year in 1,000 patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study
J Clin Oncol (Meeting Abstracts) 2004 22: 516. [Abstract]  

T. Whelan, P. Goss, J. Ingle, J. Pater, L. Shepherd, M. Palmer, D. Tu, N. Robert, S. Martino, and H. Muss

Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen
J Clin Oncol (Meeting Abstracts) 2004 22: 517. [Abstract]  

P. E. Lonning, J. Geisler, L. E. Krag, L. Ottestad, Y. Bremnes, A. I. Hagen, E. Schlichting, A. Polli, J. Paolini, and G. Massimini

Effect of exemestane on bone: A randomized placebo controlled study in postmenopausal women with early breast cancer at low risk
J Clin Oncol (Meeting Abstracts) 2004 22: 518. [Abstract]  

V. F. Semiglazov, V. Semiglazov, V. Ivanov, A. Bozhok, E. Ziltsova, R. Paltuev, G. Dashian, A. Kletzel, E. Topuzov, and L. Berstein

The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 519. [Abstract]  

A. U. Buzdar, K. Hunt, T. Smith, D. Francis, M. Ewer, D. Booser, E. Singletary, T. Buchholz, A. Sahin, and G. N. Hortobagyi

Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease
J Clin Oncol (Meeting Abstracts) 2004 22: 520. [Abstract]  

T. R. J. Evans, A. Yellowlees, E. Foster, H. Earl, D. A. Cameron, A. W. Hutcheon, R. E. Coleman, J. Crown, R. C. Leonard, and J. L. Mansi

Phase III randomised trial of doxorubicin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 521. [Abstract]  

I. A. Olivotto, C. Bajdik, P. M. Ravdin, B. Norris, A. J. Coldman, C. Speers, S. Chia, and K. Gelmon

An independent population-based validation of the adjuvant decision-aid for stage I-II breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 522. [Abstract]  

N. Harbeck, R. E. Kates, M. P. Look, and J. A. Foekens

Pooled analysis (n=8,377) evaluates predictive impact of uPA and PAI-1 for response to adjuvant therapy in breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 523. [Abstract]  

J. Ragaz, K. Miller, S. Badve, Y. Dayachko, S. Dunn, T. Nielsen, A. Brodie, D. Huntsman, C. Bajdik, and G. Sledge

Adverse association of expressed vascular endothelial growth factor (VEGF) with long-term outcome of stage I-III breast cancer (BrCa), with co-expression data of VEGF and Her2, Cox2, uPA and ER. Results from the British Columbia Tissue Microarray Project
J Clin Oncol (Meeting Abstracts) 2004 22: 524. [Abstract]  

S. Maier, I. Nimmrich, A. Marx, S. Eppenberger-Castori, F. Jaenicke, A. Paradiso, F. Spyratos, J. Foekens, M. Schmitt, and N. Harbeck

DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 525. [Abstract]  

T. Saarto, L. Vehmanen, C. Blomqvist, and I. Elomaa

Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 527. [Abstract]  

T. Powles, A. Paterson, E. McCloskey, M. Kurkilahti, and J. Kanis

Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial
J Clin Oncol (Meeting Abstracts) 2004 22: 528. [Abstract]  

A. Jaschke, G. Bastert, E. F. Solomayer, S. Costa, F. Schuetz, and I. J. Diel

Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up
J Clin Oncol (Meeting Abstracts) 2004 22: 529. [Abstract]  

I. Kokufu, N. Kohno, S. Takao, M. Yamamoto, M. Miyashita, S. Kohno, and F. Kimura

Adjuvant pamidronate (PMT) therapy for the prevention of bone metastasis in breast cancer (BC) patients (pts) with four or more positive nodes
J Clin Oncol (Meeting Abstracts) 2004 22: 530. [Abstract]  

J. Geisler, P. E. Lonning, L. E. Krag, L. Ottestad, Y. Bremnes, A. I. Hagen, E. Schlichting, E. S. Ofjord, A. Polli, and G. Massimini

Estrogens and bone metabolism in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomized placebo-controlled study
J Clin Oncol (Meeting Abstracts) 2004 22: 531. [Abstract]  

M. Colleoni, S. Gelber, R. Snyder, S. B. Holmberg, M. Fey, B. Thuerlimann, J. Lindtner, M. Byrne, C. Mendiola, and A. S. Coates

Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with node-positive (N+), early stage breast cancer: first results of International Breast Cancer Study Group Trial 13–93
J Clin Oncol (Meeting Abstracts) 2004 22: 532. [Abstract]  

D. Wallwiener, K. Possinger, P. Schmid, V. Tarutinov, L. Suchina, H. Hillger, E. Kienle, L. Maubach, S. Kahlert, and M. Untch

A phase III trial comparing adjuvant treatment with leuprorelin acetate 3M-Depot for 24 months with CMF chemotherapy in ER/PR + node + pre-perimenopausal breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 533. [Abstract]  

G. Von Minckwitz, E. Graf, M. Geberth, W. Eiermann, W. Jonat, B. Conrad, K. Brunnert, B. Gerber, H. H. Zippel, and M. Kaufmann

Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 trial
J Clin Oncol (Meeting Abstracts) 2004 22: 534. [Abstract]  

J. R. Yarnold, J. M. Bliss, H. Earl, D. George, D. Lawrence, S. H. Mortazavi, T. J. Perren, V. Raina, and D. Spooner

Ovarian ablation (OA) in pre-menopausal women with early breast cancer prescribed 5 years tamoxifen (T) or T plus chemotherapy (CT)–results from the UK NCRI Adjuvant Breast Cancer (ABC) international trial of 2,144 patients
J Clin Oncol (Meeting Abstracts) 2004 22: 535. [Abstract]  

J. Robertson, E. Gutteridge, K. L. Cheung, S. Pinder, and A. Wakeling

Oestrogen receptor expression in human breast cancer during long-term fulvestrant treatment
J Clin Oncol (Meeting Abstracts) 2004 22: 536. [Abstract]  

M. Dowsett and I. E. Smith

Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 537. [Abstract]  

M. Tubiana-Hulin and F. Spyratos

Response to neo-adjuvant exemestane in post-menopausal breast cancer patients: correlation with biological factors measured by real-time quantitative RT-PCR (QRT-PCR)
J Clin Oncol (Meeting Abstracts) 2004 22: 538. [Abstract]  

A. Franco, N. Col, and R. T. Chlebowski

Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a meta-analysis
J Clin Oncol (Meeting Abstracts) 2004 22: 539. [Abstract]  

R. Leonard, N. Bundred, A. Buzdar, P. Canney, D. Rea, A. Stewart, and M. Verrill

Trilostane, an effective signal transduction inhibitor for advanced ER+ve and ER-ve post-menopausal breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 540. [Abstract]  

S. Massarweh, C. K. Osborne, M. Dipietro, A. E. Wakeling, and R. Schiff

Tamoxifen's agonist effect on breast cancer growth is mediated by activation of EGFR/HER-2 with preservation of its antagonist effect on ER-dependent gene expression
J Clin Oncol (Meeting Abstracts) 2004 22: 541. [Abstract]  

P. Fumoleau, M. Campone, D. Vorobiof, M. Casado, P. Ruff, S. Khoo Kei, H. Cortes-Funes, S. Khalfallah, I. Caroff, and C. Colin

Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure
J Clin Oncol (Meeting Abstracts) 2004 22: 542. [Abstract]  

J. L. Blum, M. A. Savin, G. Edelman, J. E. Pippen, N. Robert, J. Sandbach, S. Carrasco, and J. A. O'Shaughnessy

Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel
J Clin Oncol (Meeting Abstracts) 2004 22: 543. [Abstract]  

J. Baselga, P. Fumoleau, M. Gil, R. Colomer, H. Roche, H. Cortes-Funes, H. Burstein, P. Kaufman, S. Kong, and L. Moore

Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results
J Clin Oncol (Meeting Abstracts) 2004 22: 544. [Abstract]  

J. A. Low, S. B. Wedam, A. Brufsky, A. Berman, E. Croarkin, R. Parks, S. M. Steinberg, N. Mannan, T. Fojo, and S. M. Swain

A phase 2 trial of BMS-247550 (ixabepilone), an epothilone B analog, given daily x 5 in breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 545. [Abstract]  

J. Brown, J. Von Roenn, R. O'Regan, R. Bergan, S. Badve, A. Rademaker, S. Feehan, J. Petersen, M. Patton, and W. Gradishar

A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 546. [Abstract]  

H. J. Burstein, B. Overmoyer, R. Gelman, P. Silverman, J. Savoie, K. Clarke, L. Dumadag, J. Younger, and E. P. Winer

Rebeccamycin analog for refractory breast cancer: a randomized phase II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 547. [Abstract]  

F. A. Tager and P. S. McKinley

Cognitive functioning before chemotherapy treatment in women with breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 548. [Abstract]  

M. Ruzich, B. Ryan, C. Owen, A. Delahunty, and R. Stuart-Harris

A prospective evaluation of cognitive function in patients with early breast cancer receiving adjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 549. [Abstract]  

L. Gladieff, P. Fumoleau, P. Kerbrat, J. Bonneterre, F. Mayer, M. Namer, A. Monnier, M.-J. Goudier, E. Luporsi, and H. Roche

Which are the interactions between baseline body mass index (BMI), toxicity of chemotherapy (CT), and efficacy of adjuvant treatments? 9-year follow-up results of French Adjuvant Study Group (FASG) trials
J Clin Oncol (Meeting Abstracts) 2004 22: 550. [Abstract]  

H. Simon, A. Monnier, M. Namer, H. Roche, P. Fumoleau, P. Kerbrat, J. Bonneterre, P. Clavere, and E. Luporsi

Prognostic factors of contralateral breast cancer (CBC) in 3,653 early breast cancer (EBC) patients (pts): 9-year follow-up results of French Adjuvant Study Group (FASG) trials
J Clin Oncol (Meeting Abstracts) 2004 22: 551. [Abstract]  

A. Tinker, C. Speers, J. Barnett, I. Olivotto, and S. Chia

Impact of reduced dose intensity of adjuvant anthracycline based chemotherapy in a population based cohort of stage I-II breast cancers
J Clin Oncol (Meeting Abstracts) 2004 22: 552. [Abstract]  

G. G. Steger, E. Kubista, H. Hausmaninger, M. Gnant, C. Tausch, A. Lang, H. Samonigg, A. Galid, and R. Jakesz

6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14
J Clin Oncol (Meeting Abstracts) 2004 22: 553. [Abstract]  

F. Icli, H. Akbulut, D. Dincol, H. Onur, A. Demirkazik, R. Cam, F. Cay, S. Demirci, A. Uner, and S. Erekul

Addition of 2 cycles of EP (Etoposide + Cisplatin) to the 4 cycles of adjuvant AC (doxorubicin + cyclophosphamide) improves the survival in node positive patients with breast cancer after 10 years
J Clin Oncol (Meeting Abstracts) 2004 22: 554. [Abstract]  

T. A. Buchholz, W. A. Woodward, S. L. Tucker, E. A. Strom, K. K. Hunt, A. U. Buzdar, G. H. Perkins, N. R. Schechter, and G. N. Hortobagyi

Defining the competing risk of local-regional and distant recurrence in 1,256 patients treated with mastectomy and doxorubicin-based adjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 555. [Abstract]  

S. J. Katz, P. M. Lantz, N. K. Janz, A. Fagerlin, B. Salem, I. Lakhani, and M. Morrow

Shared decision-making and surgical treatment for breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 556. [Abstract]  

M. Morrow, P. Lantz, N. Janz, A. Fagerlin, M. Mujahid, and S. Katz

Patterns and correlates of breast reconstruction: results of a population based study
J Clin Oncol (Meeting Abstracts) 2004 22: 557. [Abstract]  

M. Schaapveld, R. Otter, E. G. E. De Vries, W. T. A. Van der Graaf, J. De Vries, and P. H. B. Willemse

The number of histologically examined axillary lymph nodes can improve the prediction of individual prognosis of primary breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 558. [Abstract]  

G. Zavagno, G. L. De Salvo, G. Scalco, F. Bozza, R. Marconato, L. Barutta, C. Racano, D. Casara, and M. Lise

Sentinella-GIVOM, a randomized clinical trial (RCT) on sentinel node biopsy (SNB) versus axillary lymph node dissection (ALND) in breast cancer (BC): results of first interim analysis
J Clin Oncol (Meeting Abstracts) 2004 22: 559. [Abstract]  

B. Taback, N. Hansen, K. Conway, and A. Giuliano

Recurrence patterns following a negative sentinel lymph node biopsy in patients with early-stage breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 560. [Abstract]  

Y. Xing, M. Ding, D. Cox, M. I. Ross, K. K. Hunt, and J. N. Cormier

Meta-analysis of sentinel lymph node biopsy following preoperative chemotherapy in patients with operable breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 561. [Abstract]  

C. Peters-Engl, P. Konstantiniuk, C. Tausch, A. Haid, B. Hoffmann, M. Jagoutz-Herzlinger, F. Kugler, S. Redtenbacher, S. Roka, and P. Schrenk

The impact of preoperative breast biopsy on the risk of sentinel lymph node metastases: analysis of 2502 cases from the Austrian Sentinel Node Biopsy Study Group
J Clin Oncol (Meeting Abstracts) 2004 22: 562. [Abstract]  

C. Correa, W.-T. Hwang, V. A. Ferrari, H. I. Litt, L. J. Solin, and E. E. Harris

Late myocardial perfusion defects in left versus right-sided radiotherapy (RT) for breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 563. [Abstract]  

R. R. Kuske, K. Winter, D. W. Arthur, J. Bolton, R. A. Rabinovitch, J. R. White, W. F. Hanson, and R. M. Wilenzick

A phase II trial of brachytherapy alone following lumpectomy for stage I or II breast cancer: initial outcomes of RTOG 9517
J Clin Oncol (Meeting Abstracts) 2004 22: 565. [Abstract]  

L. G. Dressler, G. Broadwater, D. Berry, C. Cirrincione, D. Cowan, L. Harris, D. Moore, H. Muss, D. Hayes, and M. Ellis

A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome
J Clin Oncol (Meeting Abstracts) 2004 22: 566. [Abstract]  

E. A. Perez, V. J. Suman, N. E. Davidson, S. Martino, P. A. Kaufman, W. L. Lingle, P. J. Flynn, J. N. Ingle, D. Visscher, and R. B. Jenkins

HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial
J Clin Oncol (Meeting Abstracts) 2004 22: 567. [Abstract]  

D. V. Miller, R. B. Jenkins, W. L. Lingle, N. E. Davidson, P. A. Kaufman, S. Martino, S. R. Dakhil, and E. A. Perez

Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial
J Clin Oncol (Meeting Abstracts) 2004 22: 568. [Abstract]  

G. H. Raab, B. Hoegel, J. Biebl, and W. Eiermann

Chromogen in situ hybridisation (CISH) for HER2 assessment is highly concordant with FISH in core cut biopsies of primary T2 breast cancers
J Clin Oncol (Meeting Abstracts) 2004 22: 569. [Abstract]  

B. Leyland-Jones, M. Marty, J. Baselga, U. Gatzemeier, C. Barton, and S. Lennon

Effects of trastuzumab (H) and chemotherapy on circulating HER2 extracellular domain (ECD) in patients with metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC)
J Clin Oncol (Meeting Abstracts) 2004 22: 570. [Abstract]  

L. Del Mastro, P. Bruzzi, M. Venturini, G. Cavazzini, A. Contu, L. Gallo, F. Testore, B. Castagneto, A. Lavarello, and R. Rosso

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy (CT) in early breast cancer (BC) patients
J Clin Oncol (Meeting Abstracts) 2004 22: 571. [Abstract]  

V. Valero, E. Gill, V. Paton, H.-Y. Chang, A. U. Buzdar, G. Park, G. Hortobagyi, and M. Ewer

Normal cardiac biopsy results following co-administration of doxorubicin (A), Cyclophosphamide (C) and trastuzumab (H) to women with HER2 positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 572. [Abstract]  

N. J. Robert, B. Leyland-Jones, L. Asmar, R. J. Belt, D. Ilegbodu, D. M. Loesch, R. N. Raju, M. Cobleigh, K. S. Albain, and D. J. Slamom

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival
J Clin Oncol (Meeting Abstracts) 2004 22: 573. [Abstract]  

M.-C. Gast, J. Bonfrer, E. Rutgers, J. Schellens, and J. Beijnen

New discriminatory serum protein profiles in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 574. [Abstract]  

V. Bramwell, G. Doig, A. Tuck, S. Wilson, K. Tonkin, T. Vandenberg, and A. Chambers

Osteopontin (OPN): A novel tumor marker of potential utility in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 575. [Abstract]  

P. Wulfing, J. Tio, C. Kersting, B. Sonntag, H. Buerger, C. Wulfing, U. Euler, W. Boecker, A. H. Tulusan, and L. Kiesel

Use of endothelin-A-receptor expression to predict poor response to primary chemotherapy in locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 576. [Abstract]  

X. Yang, A. R. Tan, D. Nguyen, S. Lipkowitz, and S. M. Swain

Gene expression profile changes following erlotinib treatment in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 577. [Abstract]  

S. B. Wedam, J. A. Low, X. Yang, C. Chow, A. Berman, R. Eulate, D. Danforth, S. M. Hewitt, S. M. Steinberg, and S. M. Swain

A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 578. [Abstract]  

W. Janni, B. Rack, C. Schindlbeck, B. Strobl, D. Rjosk, S. Braun, H. Sommer, K. Pantel, B. Gerber, and K. Friese

Association of persistence of isolated tumor cells (ITC) in bone marrow (BM) of breast cancer patients with risk for relapse
J Clin Oncol (Meeting Abstracts) 2004 22: 579. [Abstract]  

A. Llombart-Cussac, G. Moreno-Bueno, A. Ruiz, J. Albanell, J. I. Mayordomo, V. Carñana, V. Guillem, R. Diaz-Uriarte, J. Palacios, and I. Garcia-Ribas

Gene expression profiling (GEP) for the prediction of response to neoadjuvant paclitaxel and gemcitabine in breast cancer (BC). Preliminary results from a Phase II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 580. [Abstract]  

D. McKillop, G. Raab, H. Eidtmann, A. Furnival, A. Riva, J. Forbes, J. Mackey, M. P. Spence, M. Koehler, and D. Slamon

Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103)
J Clin Oncol (Meeting Abstracts) 2004 22: 581. [Abstract]  

M.-L. W. Ah-See, A. Makris, N. J. Taylor, R. J. Burcombe, M. Harrison, J. J. Stirling, P. I. Richman, M. O. Leach, and A. R. Padhani

Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in primary breast cancer?
J Clin Oncol (Meeting Abstracts) 2004 22: 582. [Abstract]  

T. Delozier, C. Ségura, C. Levy, C. Delcambre, D. Allouache, O. Switsers, J.-M. Ollivier, B. Vié, F. Joly, and J.-Y. Génot

Reducing dose density in adjuvant chemotherapy (C) is detrimental in early breast cancer (EBC). A review of 872 adjuvant treatments in Centre François Baclesse
J Clin Oncol (Meeting Abstracts) 2004 22: 583. [Abstract]  

B. Gerber, W. Janni, A. Krause, H. Müller, T. Reimer, J. Makovitzky, G. Kundt, and K. Friese

Prevention of repeated benign endometrial pathology in postmenopausal women with breast cancer and tamoxifen-induced endometrial pathology: A randomized trial comparing anastrozole and tamoxifen
J Clin Oncol (Meeting Abstracts) 2004 22: 584. [Abstract]  

G. N. Hortobagyi, S.-W. Kau, A. U. Buzdar, R. L. Theriault, D. J. Booser, K. Gwyn, and V. Valero

What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis?
J Clin Oncol (Meeting Abstracts) 2004 22: 585. [Abstract]  

H. Inaji, Y. Park, K. Okamura, S. Mitsuyama, T. Saito, J. Koh, S. Kyono, K. Higaki, H. Koyama, and T. Suzuki

A randomized controlled study comparing CMF plus TAM with UFT plus TAM as postoperative adjuvant therapy in women with node-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 586. [Abstract]  

H. Sommer, W. J. Janni, B. Rack, D. Steinfeld, W. Simon, D. Augustin, M. Heinrigs, F. V. Bismarck, N. Harbeck, and M. Kiechle

The ADEBAR-trial: Effect of participation in a randomized phase III study (evaluating the role of adjuvant docetaxel in high-risk breast cancer patients) on treatment strategies and individual patient care in recruiting centers
J Clin Oncol (Meeting Abstracts) 2004 22: 587. [Abstract]  

M. Kaufmann, E. Graf, W. Jonat, W. Eiermann, H. H. Zippel, M. Geberth, B. Conrad, G. Gademann, and K. D. Schulz

Goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with breast cancer. GABG trial IV-B-93
J Clin Oncol (Meeting Abstracts) 2004 22: 588. [Abstract]  

S. Kuemmel, J. Krocker, A. Kohls, M. Budner, G.-P. Breitbach, K. Ruhland, U. Köhler, B. Reischauer, J.-U. Blohmer, and D. Elling

A phase III randomised trial comparing the tolerability of dose-dense chemotherapy in older to that in younger breast cancer patients with four or more positive lymph nodes
J Clin Oncol (Meeting Abstracts) 2004 22: 589. [Abstract]  

G. Y. Locker

An economic evaluation of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer (EBC) from a US healthcare perspective
J Clin Oncol (Meeting Abstracts) 2004 22: 590. [Abstract]  

N. Love, P. Ravdin, G. Hortobagyi, G. Grana, M. F. Paley, and L. Poltorack

Influence of prior therapy on breast cancer survivors' preferences for adjuvant systemic therapy in hypothetical scenarios
J Clin Oncol (Meeting Abstracts) 2004 22: 591. [Abstract]  

M. E. Marty, R. C. Coombes, C. Peckitt, F. R. Pérez López, A. Tres, F. Morvan, N. Tubiana-Mathieu, M. Espié, and J. M. Bliss

Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate & fluorouracil (CMF) vs fluorouracil, epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 592. [Abstract]  

C. McNeil, F. Collinson, K. Smith, R. Dunleavey, J. Boyages, and R. Kefford

Delay in conventional breast cancer treatment associated with alternative therapy usage
J Clin Oncol (Meeting Abstracts) 2004 22: 593. [Abstract]  

K. Pollow, W. Schoenegg, H. Koelbl, R. Kreienberg, A. Dubois, D. Elling, K.-J. Winzer, U. Koehler, and G. Hoffmann

Safety and tolerability of adjuvant exemestane plus goserelin with or without tibolone in receptor-positive, node-negative primary breast cancer in premenopausal women: The final results of the randomized multicenter ADAGIO pilot study
J Clin Oncol (Meeting Abstracts) 2004 22: 594. [Abstract]  

D. W. Rea, L. Hiller, H. M. Earl, J. A. Dunn, S. Bathers, D. Spooner, R. J. Grieve, R. K. Agrawal, and C. J. Poole

Tolerability and efficacy of classical CMF (cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT)
J Clin Oncol (Meeting Abstracts) 2004 22: 595. [Abstract]  

A. Rodriguez-Lescure, M. Martin, A. Ruiz, E. Alba, L. Calvo, M. Ruiz-Borrego, B. Munarriz, J. M. Lopez-Vega, and C. A. Rodriguez

Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: Safety analysis of GEICAM 9906 trial
J Clin Oncol (Meeting Abstracts) 2004 22: 596. [Abstract]  

R. Sainsbury, G. Locker, and J. Cuzick

The use of adjuvant chemotherapy in the ATAC trial: Nationality correlates with the use of chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 597. [Abstract]  

J. M. Sun, W. Han, D. W. Kim, T. Y. Kim, I. A. E. Park, D. Y. Noh, D. S. Heo, Y. J. Bang, K. J. Choe, and N. K. Kim

Clinical relevance of HER-2 expression in node-negative breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 598. [Abstract]  

P. Bougnoux, M. Combe, M.-J. Goudier, T. Facchini, and V. Lotz

Phase II randomized trial of docetaxel (D) monotherapy vs epirubicin plus docetaxel (ED) as neoadjuvant treatment of operable breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2004 22: 599. [Abstract]  

Y. Eralp, T. L. Smith, S.-W. Kau, V. Valero, A. Buzdar, G. N. Hortobagyi, and B. Arun

Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger
J Clin Oncol (Meeting Abstracts) 2004 22: 600. [Abstract]  

G. Frasci, G. D'Aiuto, P. Comella, R. Thomas, M. Rinaldo, M. Di Bonito, R. Rubulotta, S. Bonagura, M. Licenziato, and G. Comella

Two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration for the treatment of large operable breast cancer. SICOG 0105 phase II study
J Clin Oncol (Meeting Abstracts) 2004 22: 601. [Abstract]  

M. F. D. Gaui, R. Salgado, C. G. Ferreira, and N. Spector

Second-line neoadjuvant chemotherapy (NEO) with cisplatin (C), 5 fluorouracil (5FU) and radiotherapy (XRT) for locally advanced breast (LABC) refractory to anthracyclines: Evaluation after a long-term follow up
J Clin Oncol (Meeting Abstracts) 2004 22: 602. [Abstract]  

M. J. Gil Gil, A. Barnadas, L. Cirera, I. Tusquets, M. Muñoz, A. Arcusa, L. Prieto, A. Moreno, J. Graupera, and M. Margeli

Primary hormonal therapy with exemestane in patients with breast tumors >3 cm in diameter: Results of a Spanish multicenter phase II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 603. [Abstract]  

B. T. J. Hennessy, H. Kuerer, A. Sahin, A. U. Buzdar, S. W. Kau, S. E. Singletary, G. N. Hortobagyi, and V. Valero

Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center experience
J Clin Oncol (Meeting Abstracts) 2004 22: 604. [Abstract]  

M. T. Ionta, A. Scanu, F. Atzori, D. Vacca, A. Contu, A. Farris, V. Lorusso, S. Palmeri, L. Minerba, and B. Massidda

Unexpectedly high survival rate in very poor prognosis stage III B breast cancer patients receiving cisplatin-based primary chemotherapy. A multicenter Italian study
J Clin Oncol (Meeting Abstracts) 2004 22: 605. [Abstract]  

J. L. Jones, E. Rhei, M. A. Gadd, M. Howard-Mcnatt, K. S. Hughes, B.-A. Lesnikoski, R. L. Christian, J. T. Rabban, C. Kaelin, and B. L. Smith

Predictive value of sentinel lymph node biopsy prior to neoadjuvant chemotherapy in clinically node negative breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 606. [Abstract]  

H. G. Lee, J. J. Lee, K.-H. Jung, Y. Kwon, E. H. Shin, K.-W. Chung, K. H. Shin, E.-A. Kim, E. S. Lee, and J. Ro

Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): Interim analysis
J Clin Oncol (Meeting Abstracts) 2004 22: 607. [Abstract]  

P. Sanchez-Rovira, B. Duenas, M. Cidraque, R. Duenas, A. Jaen, A. Sanchez, E. Martinez, B. Medina, E. Carrasco, and A. Lozano

Dose-dense and sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab as neoadjuvant chemotherapy in stage II and III breast cancer. A phase II and pharmacogenomic study
J Clin Oncol (Meeting Abstracts) 2004 22: 608. [Abstract]  

N. Sato, M. Sano, M. Hino, M. Kimura, M. Fujimori, K.-I. Ito, K. Maeno, H. Nakagomi, and K. Negishi

Neoadjuvant paclitaxel for operable breast cancer: Multicenter phase II trial with clinical outcomes, analysis of mutation of the class I ß-tubulin gene
J Clin Oncol (Meeting Abstracts) 2004 22: 609. [Abstract]  

R. S. Davidson, M. Chaudhry, R. Localio, M. D. Schnall, and S. M. Domchek

Predicting the extent of invasive disease by MRI to enhance the use of minimally invasive techniques in the management of early stage breast carcinoma
J Clin Oncol (Meeting Abstracts) 2004 22: 610. [Abstract]  

I. Germain, A. Fortin, A. Dagnault, T. T. Vu, and M. Larochelle

The value of the number of nodes removed (or the ratio of involved nodes) as a prognostic factor in breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 611. [Abstract]  

C. G. Hargon, G. Burton, B. Li, F. Ampil, and D. Lillian

6FDG PET scan evaluation of suspicious breast lesions developing after breast conservation therapy for breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 612. [Abstract]  

T. K. Helmberger, V. Heinemann, C. Vick, A. Wallnöfer, A. Gotz, and M. F. Reiser

Percutaneous radiofrequency ablation (RFA) of hepatic metastases in patients with metastatic breast cancer: An interim analysis
J Clin Oncol (Meeting Abstracts) 2004 22: 613. [Abstract]  

F. Nakhlis, S. Hurwitz, K. A. Mayzel, E. Levin, M. M. Duggan, and M. J. Lawler

Preoperative breast MRI: Who should get it?
J Clin Oncol (Meeting Abstracts) 2004 22: 614. [Abstract]  

J. Shen, K. K. Hunt, N. Q. Mirza, S. Krishnamurthy, S. E. Singletary, H. M. Kuerer, F. Meric-Bernstam, B. Feig, M. I. Ross, and G. V. Babiera

Intramammary lymph node metastases are an independent predictor in breast cancer outcomes
J Clin Oncol (Meeting Abstracts) 2004 22: 615. [Abstract]  

R. H. I. Andtbacka, G. Babiera, E. Singletary, K. K. Hunt, F. Meric-Bernstam, B. Feig, F. Ames, M. Ross, Y. Dejesus, and H. M. Kuerer

The incidence, prophylaxis and treatment of venous thromboembolism in patients undergoing breast cancer surgery
J Clin Oncol (Meeting Abstracts) 2004 22: 616. [Abstract]  

E. G. C. Brain, T. Bachelot, D. Serin, Y. Graïc, J. C. Eymard, J. M. Extra, M. Combe, C. Nogues, and J. Rouëssé

Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pN0) and limited node positive (pN+3) breast cancer (BC) patients (pts): First analysis of toxicity
J Clin Oncol (Meeting Abstracts) 2004 22: 617. [Abstract]  

F. Efficace, P. Therasse, M. Piccart, C. Coens, K. Van Steen, M. Welnicka-Jaskiewicz, T. Cufer, M. Lichinitser, L. Shepherd, and A. Bottomley

Predicting survival with health-related quality of life scores in locally advanced breast cancer: Results from an international randomized controlled trial
J Clin Oncol (Meeting Abstracts) 2004 22: 618. [Abstract]  

T. D. Szucs, R. Leonard, R. Pettengell, R. Paridaens, C. Jackisch, M. Constenla, A. Bosly, and M. Schwenkglenks

Dose-limiting effects of neutropenic events in six European audits of adjuvant breast cancer chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 619. [Abstract]  

M. Martin, A. Lluch, M. A. Seguí, A. Antón, A. Ruiz, M. Ramos, A. Rodríguez-Lescure, and E. Adrover

Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study
J Clin Oncol (Meeting Abstracts) 2004 22: 620. [Abstract]  

C. Moinpour, J. Wu, G. Donaldson, A. Liepa, A. Melemed, J. Oshaughnessy, E. Rappold, and K. Albain

Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study
J Clin Oncol (Meeting Abstracts) 2004 22: 621. [Abstract]  

J. E. Mortimer, B. Burke, S. Fisher, and Y. Podbilewicz-Schuller

Changes in sexual function over time in women receiving adjuvant therapy for early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 622. [Abstract]  

C. L. Shapiro, K. M. Carpenter, and B. L. Andersen

Sexual behavior (SB) and relationship satisfaction after first distant recurrence (REC) in metastatic breast cancer (MBC): Preliminary results from prospective trials
J Clin Oncol (Meeting Abstracts) 2004 22: 623. [Abstract]  

K. D. Voduc, S. Tyldesley, and S. Chia

Risk of radiation pneumonitis in breast cancer patients treated with adjuvant taxanes and radiation
J Clin Oncol (Meeting Abstracts) 2004 22: 624. [Abstract]  

X. Yu, S. Zhou, D. Kahn, D. R. Hollis, R. G. Prosnitz, P. H. Hardenbergh, M. A. Blazing, T. Wong, S. Borges-Neto, and L. B. Marks

Persistence of radiation (RT)-induced cardiac perfusion defects 3–5 years post RT
J Clin Oncol (Meeting Abstracts) 2004 22: 625. [Abstract]  

R. Bartsch, U. Pluschnig, C. Wenzel, D. Hussian, G. J. Locker, R. Mader, C. C. Zielinski, and G. G. Steger

Oral vinorelbine in the treatment of advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 626. [Abstract]  

J.-U. Blohmer, M. Hauschild, J. Hilfrich, A. Kleine-Tebbe, S. Kuemmel, and W. Lichtenegger

Safety and efficacy of first-line epirubicin–docetaxel (ED) versus epirubicin–cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 627. [Abstract]  

D. A. Cameron, E. Winer, S. Campos, and J.-P. Guastalla

A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease
J Clin Oncol (Meeting Abstracts) 2004 22: 628. [Abstract]  

P. Carlini, E. Bria, D. Giannarelli, G. Ferretti, P. Papaldo, A. Fabi, E. Ruggeri, M. Milella, E. Terzoli, and F. Cognetti

New aromatase inhibitors (AIs) as 2^nd-line endocrine therapy (ET) in metastatic breast cancer (MBC): A comprehensive review of 5832 women from 14 phase III trials
J Clin Oncol (Meeting Abstracts) 2004 22: 629. [Abstract]  

S. K. Chia, M. Clemons, L. A. Martin, A. Rodgers, K. Gelmon, and L. Panasci

A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 630. [Abstract]  

J. P. Crown, S. Leyvraz, M. Verrill, V. Guillem, A. Efremidis, J. Garcia-Conde Bru, R. Welch, A. Montes, R. Leonard, and J. Baselga

Effect of tandem high-dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: Mature results of the IBDIS-I
J Clin Oncol (Meeting Abstracts) 2004 22: 631. [Abstract]  

A. A. Epenetos, R. Ceriani, J. Peterson, P. Cagnoni, Y. Nieto, and R. Jones

Phoenix- A humanised ⁹⁰Y-conjugated monoclonal antibody for the treatment of relapsed breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 632. [Abstract]  

K. A. Gelmon, T. Whelan, J. Latreille, I. Olivotto, C. Sawka, K. Pritchard, S. Bondy, R. Cosby, R. Roberts, and M. Levine

Patterns of trastuzumab (T) use in three Canadian provinces
J Clin Oncol (Meeting Abstracts) 2004 22: 633. [Abstract]  

A. Gennari, P. Conte, C. Orlandini, V. Guarneri, R. Rosso, and P. Bruzzi

Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001
J Clin Oncol (Meeting Abstracts) 2004 22: 634. [Abstract]  

W. Gradishar, S. Wolinsky, T. Vishalpura, B. Nightengale, and T. Bramley

Cost-effectiveness of nanoparticle albumin-bound (nab) paclitaxel (ABX) vs Cremophor-based paclitaxel (CP) in the treatment of metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 635. [Abstract]  

V. Guillem Porta, M. Martin, M. Gil Gil, P. Kellokumpu-Lehtinen, F. Majois, J. Gasmi, D. Aubert, and O. Bourrillon

Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC): Impact on clinical response and cardiac function
J Clin Oncol (Meeting Abstracts) 2004 22: 636. [Abstract]  

E. Heidemann, G. V. Minckwitz, N. Holländer, R. Souchon, M. Clemens, M. Mahlke, B. Eggeling, A. Marseille, G. Krekeler, and M. Kaufmann

Mitoxantrone plus docetaxel vs single agent mitoxantrone in metastatic breast cancer (MBC): Results of a multicenter randomized trial
J Clin Oncol (Meeting Abstracts) 2004 22: 637. [Abstract]  

C. X. Ma, P. Steen, K. M. Rowland, R. D. Niedringhaus, J. W. Kugler, J. N. Ingle, E. A. Perez, and A. A. Adjei

A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study
J Clin Oncol (Meeting Abstracts) 2004 22: 639. [Abstract]  

L. Maiorino, G. Frasci, D'Aiuto, P. Comella, R. Thomas, D'Aniello, P. Silvestro, A. Russo, L. Lapenta, and G. Comella

Weekly cisplatin-epirubicin-paclitaxel (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). Interim analysis of the SICOG 9908 phase III trial
J Clin Oncol (Meeting Abstracts) 2004 22: 640. [Abstract]  

P. Schmid, W. Schippinger, T. Nitsch, G. Huebner, R. Kreienberg, W. Schultze, H. Hausmaninger, M. Wischnewsky, H. Samonigg, and K. Possinger

Up front tandem high-dose chemotherapy (HD) compared to standard chemotherapy with doxorubicin and paclitaxel (AT) in metastatic breast cancer (MBC): Final results of a randomized trial
J Clin Oncol (Meeting Abstracts) 2004 22: 641. [Abstract]  

D. Slamon, C. H. Yeon, T. Pienkowski, D. Northfelt, W. Eiermann, R. Patel, J. Crown, A. Riva, S. Blitz, and M. Pegram

Survival analysis from two open-label non-randomized phase II trials of trastuzumab (H) combined with docetaxel (T) and platinums (C, cisplatin or carboplatin) (TCH) in women with HER2+ advanced breast cancer (ABC)
J Clin Oncol (Meeting Abstracts) 2004 22: 642. [Abstract]  

D. A. Yardley, F. A. Greco, L. L. Porter, H. A. Burris, C. Phelps, C. Webb, L. Schlabach, L. M. Fichtel, and J. D. Hainsworth

First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 643. [Abstract]  

P. F. Lebowitz, J. Eng-Wong, F. Balis, B. Widemann, N. Jayaprakash, S. Gantz, C. Chow, M. Merino, and J. Zujewski

A phase I trial of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in hormone-receptor positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 644. [Abstract]  

S. J. Stanway, A. Purohit, L. Woo, S. Sufi, N. Dobbs, M. Elliott, B. Potter, M. Reed, and R. C. Coombes

First phase I trial of a steroid sulfatase inhibitor in breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 645. [Abstract]  

G. F. Tidmarsh, I. O. Kudajbergenova, S. N. Navrusov, and V. V. Stepula

An open label phase II trial of glufosfamide: A ß-D-glucose-linked isophosphoramide mustard given as 1-hour infusion in patients with advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 646. [Abstract]  

S. Barker, H. R. Glover, S. D. M. Malouitre, J. R. Puddefoot, and G. P. Vinson

Divergent effects of tamoxifen and trilostane in activating protein–1 gene transcription and progesterone receptor expression in breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 647. [Abstract]  

E. Gutteridge, J. M. Gee, R. I. Nicholson, and J. F. R. Robertson

Biological markers associated with response to gefitinib (ZD1839) in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 648. [Abstract]  

G. Hudelist, W. Koestler, J. Attems, K. Czerwenka, R. Mueller, M. Manavi, G. Steger, E. Kubista, C. J. Zielinski, and C. F. Singer

Active Her-2/neu signal transduction in breast cancer –relevance of a ligand-independent activation mechanism and impact on the efficacy of trastuzumab-based treatment
J Clin Oncol (Meeting Abstracts) 2004 22: 649. [Abstract]  

L. E. Krag, J. Geisler, P. E. Lonning, L. Ottestad, T. Risberg, A. I. Hagen, E. A. Lien, A. Polli, J. Paolini, and G. Massimini

Lipid and coagulation profile in postmenopausal women with early breast cancer at low risk treated with exemestane: A randomized, placebo-controlled study
J Clin Oncol (Meeting Abstracts) 2004 22: 650. [Abstract]  

M. Kusama, H. Kaise, D. Ota, S. Nakayama, T. Miisaka, A. Tsuchida, T. Aoki, Y. Hakamada, and M. Arima

Evaluation of sensitivity to 5-FU on the basis of TS and DPD activity in micro tissue specimens
J Clin Oncol (Meeting Abstracts) 2004 22: 651. [Abstract]  

S. Landt, H. Bühler, N. Vorsteher, K. Evers, B. Duvnjak, H. Adam, N. Bangemann, J. U. Blohmer, and G. Schaller

Myocardial expression of HER2 and HER4 in anthracycline-pretreated breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 652. [Abstract]  

S. E. Rivkin, A. M. Gown, J. A. Malmgren, R. J. Tickman, M. Atwood, and D. Iriarte

Vascular endothelial growth factor expression and survival in node positive breast cancer patients treated with adjuvant therapy
J Clin Oncol (Meeting Abstracts) 2004 22: 653. [Abstract]  

R. Wieder and V. Joseph

All trans-retinoic acid modulates survival signaling in dormant breast cancer cells
J Clin Oncol (Meeting Abstracts) 2004 22: 654. [Abstract]  

J. Zidan, I. Dashkovski, A. Hadary, W. Basher, and C. Cozacov

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
J Clin Oncol (Meeting Abstracts) 2004 22: 655. [Abstract]  

P. J. Barrett-Lee, J. M. Bliss, A. M. Brunt, K. Dehshiri, A. N. Harnett, L. Johnson, D. Lawrence, A. Robinson, and K. Weerasekera

Polychemotherapy (CT) in pre- and post-menopausal women with early breast cancer prescribed 5 years tamoxifen (T) –results from the UK NCRI Adjuvant Breast Cancer (ABC) international trial in 1991 patients
J Clin Oncol (Meeting Abstracts) 2004 22: 656. [Abstract]  

B. Bermejo, A. Lluch, I. Benet, J. M. Sastre, J. V. Ferrer, T. Garcia, L. Chumbes, P. Martinez, and J. Garcia-Conde

Persistence of occult metastatic cells in bone marrow after adjuvant systemic therapy predicts relapse in localized breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 657. [Abstract]  

M. Bhattacharyya, S. Vinnicombe, D. Ryan, R. Al-Mufti, R. Carpenter, and C. Gallagher

Use of magnetic resonance imaging to plan breast conserving surgery following neoadjuvant chemotherapy for early breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 658. [Abstract]  

E. Bria, C. Nisticò, F. Cuppone, D. Giannarelli, and E. Terzoli

Impact of taxanes in association with anthracyclines in 1^st line chemotherapy for metastatic breast cancer (MBC): Comprehensive review of 2805 patients in 7 phase III trials
J Clin Oncol (Meeting Abstracts) 2004 22: 659. [Abstract]  

S. Delaloge, M. Tubiana-Hulin, A. Wardley, L. Del Mastro, A. Santoro, A. Zambelli, A. Bonetti, C. Boni, F. Habib, and S. Brienza

A multistep randomized phase II/III trial comparing oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN)+FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results
J Clin Oncol (Meeting Abstracts) 2004 22: 660. [Abstract]  

T. N. Fehm, S. Becker, G. Pergola-Becker, S. Duerr-Stoerzer, E. Solomayer, and D. Wallwiener

Prediction of tumor cell dissemination in primary breast cancer by tumor biological and clinicopathological factors
J Clin Oncol (Meeting Abstracts) 2004 22: 661. [Abstract]  

S. Fracchioli, R. Bellino, R. Arisio, K. Mingrone, A. Durando, G. Giardina, D. Katsaros, M. Massobrio, M. Porpiglia, and R. Vicelli

Ductal carcinoma in situ (DCIS): USC/Van Nuys Prognostic Index (VNPI) and the impact of micropapillary histotype
J Clin Oncol (Meeting Abstracts) 2004 22: 662. [Abstract]  

A. M. Gonzalez-Angulo, S. W. Kau, K. Broglio, A. U. Buzdar, R. L. Theriault, V. Valero, N. Sneige, D. Frye, G. N. Hortobagyi, and M. Cristofanilli

Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features
J Clin Oncol (Meeting Abstracts) 2004 22: 663. [Abstract]  

J. J. Griggs, M. E. S. Sorbero, K. Sattelberg, and A. W. Dick

Does detection and treatment of ductal carcinoma in situ prevent invasive cancer?
J Clin Oncol (Meeting Abstracts) 2004 22: 664. [Abstract]  

E. Grunfeld, M. Levine, J. Julian, K. Pritchard, D. Coyle, D. Mirsky, S. Verma, S. Dent, C. Sawka, and D. Ginsburg

A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: A comparison of primary care versus specialist care
J Clin Oncol (Meeting Abstracts) 2004 22: 665. [Abstract]  

A. N. Harnett, J. M. Bliss, L. Johnson, D. Lawrence, V. Raina, and A. Robinson

Thromboembolic events (TEE) in UK NCRI Adjuvant Breast Cancer (ABC) international trial –retrospective and prospective audits
J Clin Oncol (Meeting Abstracts) 2004 22: 666. [Abstract]  

D. Hicks, M. Skacel, E. Downs-Kelly, M. Cheang, J. Pettay, T. Nielsen, D. Huntsman, R. Powell, J. Hainfeld, and T. Grogan

Invasive breast cancer clinical outcome is predicted by a novel bright-field assay for the simultaneous detection of HER2 gene amplification and protein expression (SILVERFISH)
J Clin Oncol (Meeting Abstracts) 2004 22: 667. [Abstract]  

N. Kohno, K. Aogi, H. Minami, S. Nakamura, T. Asaga, Y. Iino, T. Watanabe, C. Goessl, Y. Ohashi, and S. Takashima

A randomized, double-blind, placebo-controlled phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 668. [Abstract]  

H. Kourea, A. K. Koutras, V. Zolota, I. Grimani, E. Tzorakoeleptherakis, D. Koukouras, G. Fountzilas, H. Gogas, K. Kyriakou, and H. P. Kalofonos

Expression of cell cycle-related proteins p27kip1, p21waf1 and p53 in node-negative invasive ductal carcinoma of the breast
J Clin Oncol (Meeting Abstracts) 2004 22: 669. [Abstract]  

D. Luftner, H. Dilk, P. Henschke, R. Geppert, M. Dietel, H. Stein, K. Wernecke, K. Possinger, and B. Heine

Results of a 10-year retrospective search in two university institutes of pathology: Concordance of HER-2/neu expression of primary breast carcinomas and their metachronous distant metastases
J Clin Oncol (Meeting Abstracts) 2004 22: 670. [Abstract]  

G. H. Perkins, M. C. Green, L. P. Middleton, S. H. Giordano, S. M. Garcia, E. A. Strom, N. R. Schechter, P. Allen, T. A. Buchholz, and G. N. Hortobagyi

Medullary breast carcinoma: Outcomes and prognosis with the utilization of chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 671. [Abstract]  

J. Y. Petit, G. Curigliano, F. Bertolini, G. Peruzzotti, S. Gandini, S. Zurrida, S. Martella, R. Ghisini, F. De Braud, and A. Goldhirsch

Systemic effects of surgery: Quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-ß) in patients with breast cancer who underwent limited or extended surgery
J Clin Oncol (Meeting Abstracts) 2004 22: 672. [Abstract]  

R. G. Prosnitz, X. Yu, S. Zhou, D. Kahn, D. R. Hollis, P. H. Hardenbergh, S. Borges-Neto, T. Wong, M. A. Blazing, and L. B. Marks

Impact of patient-specific factors in the development of radiation (RT)-associated cardiac perfusion defects
J Clin Oncol (Meeting Abstracts) 2004 22: 673. [Abstract]  

J. C. Reddy, S. Rai, G. Lieberman, and P. Klein

Patient benefit from trastuzumab plus a taxane regardless of estrogen receptor (ER) status or prior adjuvant therapy for HER2+ metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 674. [Abstract]  

I. E. Smith and M. Dowsett

Assessment of lipids and bone-derived resorption products during neoadjuvant therapy with anastrozole (A), v tamoxifen (T), v combination (C) in the IMPACT trial
J Clin Oncol (Meeting Abstracts) 2004 22: 675. [Abstract]  

J. A. Sparano, U. Hopkins, S. Moulder, and L. Vahdat

A phase I trial of the farnesyl transferase inhibitor tipifarnib plus doxorubicin-cyclophosphamide in patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 676. [Abstract]  

C. L. Vogel, J. R. Mackey, and M. Martin

The role of growth factor support following neutropenic events in early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001
J Clin Oncol (Meeting Abstracts) 2004 22: 677. [Abstract]  

Z. Vujaskovic, E. Jones, E. Rosen, Z. Rabbani, S. Kim, V. Liotcheva, M. Dewhirst, T. Samulski, L. Prosnitz, and K. Blackwell

High degree of correlation between in vivo tumor oxygenation measurements and carbonic anhydrase IX tissue staining in operable human breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 678. [Abstract]  

H. Yaziji, T. S. Barry, L. C. Goldstein, H. H. Hwang, A. W. Hing, and A. M. Gown

Discrepancies between immunohistochemistry and fluorescence in situ hybridization for HER-2 testing in breast cancer: The role of a quality assurance program on a cohort of 3564 patients
J Clin Oncol (Meeting Abstracts) 2004 22: 679. [Abstract]  

C. H. Yeon, D. Slamon, R. Patel, A. Cartmell, B. Leyland-Jones, P. Klein, W. Eiermann, J. Wolter, G. Lieberman, and M. Pegram

Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT)
J Clin Oncol (Meeting Abstracts) 2004 22: 680. [Abstract]  

H. Zhao, T. Ray, P. Robinson, C. Miyamoto, and M. P. Achary

A novel DNA marker associated with breast metastasis
J Clin Oncol (Meeting Abstracts) 2004 22: 681. [Abstract]  

R. Altaha, E. Crowell, B. Ducatman, G. Higa, and J. Abraham

Risk of brain metastases in HER2/neu-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 682. [Abstract]  

B. E. Ellerin, J. Seidenfeld, and S. C. Formenti

A systematic review of post-lumpectomy radiation therapy regimens
J Clin Oncol (Meeting Abstracts) 2004 22: 683. [Abstract]  

P. Koralewski, M. Blasinska Morawiec, A. Tekiela, E. Chmielowska, M. Campone, J. Bonneterre, B. Longerey, and S. Lafaye de Micheaux

Phase I study of vinorelbine (VRL) alternating i.v. and oral in combination with docetaxel (DTX) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2004 22: 684. [Abstract]  

A. Z. Bluming

Hormone replacement therapy (HRT) in women with previously treated primary breast cancer
J Clin Oncol (Meeting Abstracts) 2004 22: 685. [Abstract]  

V. Raina, M. Bhutani, R. Bedi, A. Sharma, S. Deo, N. K. Shukla, B. K. Mohanti, and G. Rath

Analysis of early breast cancer (EBC) cases at IRCH, AIIMS, New Delhi
J Clin Oncol (Meeting Abstracts) 2004 22: 686. [Abstract]  

D. M. Mintzer, A. L. Davis, and M. Klitus

Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: The effect of taxanes
J Clin Oncol (Meeting Abstracts) 2004 22: 687. [Abstract]  

P. F. Escobar, R. Patrick, L. Rybicki, S. Grundfest-Broniatowski, J. Kim, and J. Crowe

Clinical predictors of residual breast disease after primary induction chemotherapy
J Clin Oncol (Meeting Abstracts) 2004 22: 688. [Abstract]  

M. L. Quan, R. Delgado, and K. Van Zee

Atypical vascular lesions including angiosarcoma after breast conservation
J Clin Oncol (Meeting Abstracts) 2004 22: 689. [Abstract]  

S. Wang, P. Fan, and X. Liu

Study on micrometastases in sentinel lymph node, peripheral blood and bone marrow from breast cancer patients
J Clin Oncol (Meeting Abstracts) 2004 22: 690. [Abstract]  

M. Hauschild, A. Thomas, S. Maza, S. Kuemmel, T. Fischer, P. Mallmann, D. L. Munz, and J. U. Blohmer

Sentinel node biopsy in breast cancer after neoadjuvant therapy
J Clin Oncol (Meeting Abstracts) 2004 22: 691. [Abstract]  

Z. Agur, L. Arakelyan, G. Belilty, N. Dahan, H. Harpak, Y. Kogan, Y. Merbl, A. Rabinovich, M. Shoham, and I. Ziv

Application of the Virtual Cancer Patient Engine (VCPE) for improving oncological treatment desig
J Clin Oncol (Meeting Abstracts) 2004 22: 692. [Abstract]  

P. Lind, U. Blom-Goldman, M. Anderson, B. Wennberg, and G. Svane

Prevention of radiation pneumonitis in breast cancer irradiation through dose-volume constraint
J Clin Oncol (Meeting Abstracts) 2004 22: 693. [Abstract]  

K. Motomura, S. Nagumo, C. Egawa, Y. Komoike, T. Kasugai, Y. Hasegawa, H. Inaji, and H. Koyama

Role of three axillary lymph node sampling for predicting non-sentinel node metastases in patients with breast cancer and positive sentinel node
J Clin Oncol (Meeting Abstracts) 2004 22: 694. [Abstract]  

U. Kraus-Tiefenbacher, A. Scheda, L. Bauer, F. Melchert, and F. Wenz

Intraoperative radiotherapy (IORT) as a boost in patients with early breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 695. [Abstract]  

K. Haider, G. Kornek, W. Kwasny, D. Depisch, T. Payrits, W. Scheithauer, and F. Lang

Multicenter phase II trial of gemcitabine plus liposomal doxorubicin in chemotherapeutically pretreated patients with advanced breast cancer (ABC
J Clin Oncol (Meeting Abstracts) 2004 22: 696. [Abstract]  

R. Aft, L. Ylagan, S. Sadeghi, T. Eberlein, V. Herrmann, J. Dietz, P. Fracasso, M. Naughton, and K. Weilbaecher

Effect of neoadjuvant chemotherapy on bone marrow micrometastases in women with locally advanced breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 697. [Abstract]  

H. Iwata, M. Mizutani, K. Kamei, T. Toyama, Y. Ando, D. Ota, N. Kawaguchi, C. Shigemori, and H. Iwase

A phase I/II dose-escalation study of weekly paclitaxel in combination with 5'-deoxy-5-fluorouridine for advanced or recurrent breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 698. [Abstract]  

F. Gago and D. R. Ciocca

Breast cancer patients co-expressing estrogen receptor alpha and/or progesterone receptors and HER2/neu: Response to adjuvant therap
J Clin Oncol (Meeting Abstracts) 2004 22: 699. [Abstract]  

A. Reyners, H. Hollema, and N. Mulder

Intensive chemotherapy with autologous bone marrow transplantation in patients with locally advanced breast cancer: 12-years follow-u
J Clin Oncol (Meeting Abstracts) 2004 22: 700. [Abstract]  

M. A. Lacombe, W. Al-Najjar, J. McMahon, V. Raghavan, and W. D. Bloomer

Accelerated partial breast irradiation using intensity modulated radiotherapy: Dose-volume histogram comparison with standard breast irradiatio
J Clin Oncol (Meeting Abstracts) 2004 22: 701. [Abstract]  

S. R. Bunker and C. B. Dunleavy

Fusion changes patient management with PET & C
J Clin Oncol (Meeting Abstracts) 2004 22: 702. [Abstract]  

A. Ezzat, M. Rahal, T. Twegieri, S. Akhtar, A. Al Sayed, D. Ajarim, A. Tulbah, O. Al Malik, and M. Al Shabanah

Primary chemotherapy with doxorubicin followed by docetaxel-cisplatin in locally advanced breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 703. [Abstract]  

F. Fulfaro, M. R. Valerio, G. Badalamenti, C. Arcara, G. Cicero, C. Intrivici, A. Crosta, C. Sciortino, A. Russo, and N. Gebbia

Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patient
J Clin Oncol (Meeting Abstracts) 2004 22: 704. [Abstract]  

N. Gebbia, F. Fulfaro, G. Badalamenti, C. Arcara, G. Cicero, G. Rinaldi, L. Vizzini, F. Spinnato, A. Russo, and M. R. Valerio

A phase 2 study of oxaliplatin (O) -capecitabine (C) chemotherapy in metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxane
J Clin Oncol (Meeting Abstracts) 2004 22: 705. [Abstract]  

S. Verma, V. Gallant, M. Trudeau, and S. Dahrouge

Trastuzumab (T) and docetaxel (D) for the treatment of HER2 metastatic breast cancer (MBC): A literature based (LB) and individual patient data (IPD) meta-analysis (MA) of phase II trial
J Clin Oncol (Meeting Abstracts) 2004 22: 706. [Abstract]  

H. Zafar, B. Pollock, I.-T. Yeh, and W. Knight

Her-2/Neu over expression in patients with breast cancer and early central nervous system (CNS) relaps
J Clin Oncol (Meeting Abstracts) 2004 22: 707. [Abstract]  

W. Wong, B. Pockaj, M. Halyard, R. Gray, S. Vora, S. Schild, and H. Apsey

Integration of intra-operative electron irradiation (IOERT) in breast conserving treatment for T1/T2N0 breast cancer: Early results of a phase II tria
J Clin Oncol (Meeting Abstracts) 2004 22: 708. [Abstract]  

J. P. Lamont, M. Faynsod, D. Smith, R. Pezner, and J. D. I. Ellenhorn

Evaluation of routine radiation boost following breast conservation therapy in young patient
J Clin Oncol (Meeting Abstracts) 2004 22: 709. [Abstract]  

K.-S. Khoo, M. Zaidi, V. Srimuninnimit, Z. F. Jiang, P. Prem Kumar, A. Bustam, A. H. Villalon, and M. Lehnert

Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC
J Clin Oncol (Meeting Abstracts) 2004 22: 710. [Abstract]  

M. Martino, F. Morabito, M. C. Zavettieri, M. Nardi, S. Palazzo, G. Filippelli, B. Lazzaro, S. Molica, G. Longo, and P. Iacopino

Long-term results of high-dose chemotherapy with autologous peripheral stem cells support on the outcome of progression free and overall survival in metastatic breast cancer patients classified according to a risk group scor
J Clin Oncol (Meeting Abstracts) 2004 22: 711. [Abstract]  

X. Tchiknavorian, S. Perruchio, P. Agin, A. Lachard, B. Beedassy, J. M. Blanc, and L. Cals

Retrospective analysis of 561 breast magnetic resonance imaging (MRI). The largest study to dat
J Clin Oncol (Meeting Abstracts) 2004 22: 712. [Abstract]  

N. Naqi, M. Ilyas, and R. Hashim

Skeletal related events in breast cancer patients with metastatic bone diseas
J Clin Oncol (Meeting Abstracts) 2004 22: 713. [Abstract]  

C. Wenzel, D. Hussian, R. Bartsch, U. Pluschnig, G. J. Locker, M. Gnant, R. Jakesz, C. C. Zielinski, and G. G. Steger

Feasibility of docetaxel, epirubicin, and capecitabine (TEX) plus pegfilgrastim as neoadjuvant treatment for primary breast cancer: A pilot stud
J Clin Oncol (Meeting Abstracts) 2004 22: 714. [Abstract]  

A. E. Ring, P. A. Ellis, A. Jones, C. Shannon, E. Galani, and I. E. Smith

Chemotherapy for breast cancer given during pregnancy: A case serie
J Clin Oncol (Meeting Abstracts) 2004 22: 715. [Abstract]  

A. Chan, J. Yau, S. Huan, D. Vergidis, M. Anthes, C. Falkson, A. Kirk, and H. Dhaliwal

Adherence to clinical practice guidelines for adjuvant therapy of breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 716. [Abstract]  

C. D. Cheli, R. P. Thiel, and D. Luftner

Clinical utility of a HER-2/neu assay in monitoring and predicting response to therapies in patients with metastatic breast cance
J Clin Oncol (Meeting Abstracts) 2004 22: 717. [Abstract]  

G. Sanna, A. Balduzzi, L. Franceschelli, L. Corsetto, M. G. Zampino, I. Minchella, C. Catania, K. Lorizzo, A. Rocca, and F. Nolè

An effective chemotherapy regimen for patients with heavily pretreated metastatic breast cancer (MBC) using vinorelbine (V) administered with weekly epirubicin (E) and continuous infusion of 5- fluorouracil (CIFU
J Clin Oncol (Meeting Abstracts) 2004 22: 718. [Abstract]  

L. Cals, P. Nouyrigat, X. Tchiknavorian, C. Veyret, and J. L. Wendling